# Affiris AG clinical trials: 20 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Affiris AG as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Affiris AG: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/affiris-ag

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 2, 2016 | NCT02758730 | Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients | Affiris AG | Phase 1 | Withdrawn | Parkinson's Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02758730) |
| December 2, 2015 | NCT02618941 | Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA) | Affiris AG | Phase 1 | Completed | Parkinson's Disease | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02618941) |
| July 27, 2015 | NCT02508896 | Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects | Affiris AG | Phase 1 | Completed | Hypercholesterolemia | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02508896) |
| October 21, 2014 | NCT02270489 | Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA | Affiris AG | Phase 1 | Completed | Multiple System Atrophy, Neurodegenerative Diseases | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02270489) |
| October 17, 2014 | NCT02267434 | Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease | Affiris AG | Phase 1 | Completed | Parkinson Disease, Neurodegenerative Diseases | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02267434) |
| August 13, 2014 | NCT02216188 | Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity | Affiris AG | Phase 1 | Completed | Parkinson's Disease | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02216188) |
| December 11, 2013 | NCT02008513 | Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006 | Affiris AG | Phase 2 | Terminated | Alzheimer´s Disease | 194 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02008513) |
| June 25, 2013 | NCT01885494 | AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01A | Affiris AG | Observational | Completed | Parkinson's Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01885494) |
| April 2, 2012 | NCT01568099 | Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease | Affiris AG | Phase 1 | Completed | Parkinson's Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01568099) |
| April 2, 2012 | NCT01568086 | Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A | Affiris AG | Observational | Terminated | Alzheimer's Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01568086) |
| May 23, 2011 | NCT01357629 | Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease | Affiris AG | Observational | Terminated | Alzheimer´s Disease | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01357629) |
| March 7, 2011 | NCT01309763 | Safety and Tolerability of AFFITOPE AD03 | Affiris AG | Phase 1 | Completed | Alzheimer's Disease | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01309763) |
| January 27, 2011 | NCT01284582 | Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP) | Affiris AG | Phase 1 | Completed | HDL, Drug Safety | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01284582) |
| October 21, 2010 | NCT01225809 | AD01 Follow up Extension Visit | Affiris AG | Observational | Completed | Alzheimer´s Disease | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01225809) |
| May 6, 2010 | NCT01117818 | Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's... | Affiris AG | Phase 2 | Completed | Alzheimer's Disease | 335 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01117818) |
| March 26, 2010 | NCT01093664 | Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02 | Affiris AG | Phase 1 | Completed | Alzheimer's Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01093664) |
| July 8, 2008 | NCT00711321 | Long-term Safety and Tolerability of AFFITOPE AD02 | Affiris AG | Observational | Completed | Alzheimer's Disease | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00711321) |
| July 8, 2008 | NCT00711139 | Long-term Safety and Tolerability of AFFITOPE AD01 | Affiris AG | Observational | Completed | Alzheimer's Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00711139) |
| March 12, 2008 | NCT00633841 | Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease | Affiris AG | Phase 1 | Completed | Alzheimer's Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00633841) |
| July 3, 2007 | NCT00495417 | Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease | Affiris AG | Phase 1 | Completed | Alzheimer's Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00495417) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 2 | 2 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Alzheimer Disease | 9 |
| Parkinson Disease | 6 |
| Neurodegenerative Diseases | 3 |
| Hypercholesterolemia | 1 |
| Multiple System Atrophy | 1 |
| Dementia | 1 |
| Brain Diseases | 1 |
| Nervous System Diseases | 1 |
| Tauopathies | 1 |
| Mental Disorders | 1 |
| Inhibition, Psychological | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [IP and internet law firms in the United States](https://specstream.ai/data/businesses/ip-and-internet-law-firms/united-states)
- [Marketing agencies in the United States](https://specstream.ai/data/businesses/marketing-agencies/united-states)
- [Occupational therapy clinics in the United States](https://specstream.ai/data/businesses/occupational-therapy-clinics/united-states)
- [Plasterers in the United States](https://specstream.ai/data/businesses/plasterers/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [South African restaurants in the United States](https://specstream.ai/data/businesses/south-african-restaurants/united-states)
